Literature DB >> 29931438

[Genetics of thyroid nodules and thyroid carcinoma].

D Führer1.   

Abstract

Thyroid nodules are heterogeneous tumors with variable genetic signatures. Thyroid cancers are monoclonal lesions with a defined histomorphology that largely depends on the underlying somatic mutation. While the mutation rate is generally low in differentiated thyroid cancers, poorly differentiated and anaplastic thyroid cancers show a high mutation load. The identification of somatic mutations in fine needle aspirates can be helpful for the differential diagnostics of thyroid nodules; however, a prognostic contribution is less certain. The molecular pathology of thyroid tumors is helpful for the development of targeted therapies and may infer novel immuno-oncological concepts for advanced aggressive thyroid cancers.

Entities:  

Keywords:  Molecular pathology; Oncogene addiction; Somatic mutation; Thyroid cancer; Thyroid tumor

Mesh:

Year:  2018        PMID: 29931438     DOI: 10.1007/s00108-018-0454-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  51 in total

1.  Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors:  M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 2.  Molecular pathogenesis of euthyroid and toxic multinodular goiter.

Authors:  Knut Krohn; Dagmar Führer; Yvonne Bayer; Markus Eszlinger; Volker Brauer; Susanne Neumann; Ralf Paschke
Journal:  Endocr Rev       Date:  2004-12-22       Impact factor: 19.871

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

5.  Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma.

Authors:  Kerstin Krause; Susanne Prawitt; Markus Eszlinger; Christian Ihling; Andrea Sinz; Katrin Schierle; Oliver Gimm; Henning Dralle; Frank Steinert; Sien-Yi Sheu; Kurt W Schmid; Dagmar Fuhrer
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  FOXO3a: a novel player in thyroid carcinogenesis?

Authors:  Stefan Karger; Carl Weidinger; Kerstin Krause; Sien-Yi Sheu; Thomas Aigner; Oliver Gimm; Kurt-Werner Schmid; Henning Dralle; Dagmar Fuhrer
Journal:  Endocr Relat Cancer       Date:  2008-10-09       Impact factor: 5.678

8.  Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

Authors:  Nishant Agrawal; Yuchen Jiao; Mark Sausen; Rebecca Leary; Chetan Bettegowda; Nicholas J Roberts; Sheetal Bhan; Allen S Ho; Zubair Khan; Justin Bishop; William H Westra; Laura D Wood; Ralph H Hruban; Ralph P Tufano; Bruce Robinson; Henning Dralle; Sergio P A Toledo; Rodrigo A Toledo; Luc G T Morris; Ronald A Ghossein; James A Fagin; Timothy A Chan; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Barry D Nelkin; Douglas W Ball
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

9.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.

Authors:  T Liu; N Wang; J Cao; A Sofiadis; A Dinets; J Zedenius; C Larsson; D Xu
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

10.  Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.

Authors:  Vera Tiedje; Saskia Ting; Robert Fred Walter; Thomas Herold; Karl Worm; Julia Badziong; Denise Zwanziger; Kurt Werner Schmid; Dagmar Führer
Journal:  Eur J Endocrinol       Date:  2016-06-09       Impact factor: 6.664

View more
  2 in total

1.  CD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway.

Authors:  Danzhen Yao; Jinying Xia; Jianhui Li; Jun Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

2.  Growth rates of malignant and benign thyroid nodules in an ultrasound follow-up study: a retrospective cohort study.

Authors:  Michael Cordes; Theresa Ida Götz; Karen Horstrup; Torsten Kuwert; Christian Schmidkonz
Journal:  BMC Cancer       Date:  2019-11-21       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.